<scp>PI3Kβ</scp> inhibition enhances <scp>ALK</scp> ‐inhibitor sensitivity in <scp> <i>ALK</i> </scp> ‐rearranged lung cancer-Reference-Cited by-同舟云学术

PI3Kβ inhibition enhances ALK ‐inhibitor sensitivity in ALK ‐rearranged lung cancer

Published:2023-01-25 Issue:5 Volume:17 Page:747-764
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Talwelkar Sarang S.¹²,Mäyränpää Mikko I.³,Schüler Julia⁴,Linnavirta Nora¹,Hemmes Annabrita¹,Adinolfi Simone⁵,Kankainen Matti¹,Sommergruber Wolfgang⁶⁷,Levonen Anna‐Liisa⁵,Räsänen Jari⁸,Knuuttila Aija⁹,Verschuren Emmy W.¹¹⁰¹¹^ORCID,Wennerberg Krister¹¹²^ORCID

Affiliation:

1. Institute for Molecular Medicine Finland (FIMM), HiLIFE University of Helsinki Finland

2. Institute of Biomedicine and MediCity Research Laboratories University of Turku Finland

3. Department of Pathology Helsinki University Hospital and University of Helsinki Finland

4. Charles River Research Services Germany GmbH Freiburg im Breisgau Germany

5. A. I. Virtanen Institute for Molecular Sciences University of Eastern Finland Kuopio Finland

6. Cancer Cell Signalling Boehringer Ingelheim RCV GmbH & Co KG Vienna Austria

7. Department of Biotechnology University of Applied Sciences Vienna Austria

8. Department of Thoracic Surgery, Heart and Lung Center Helsinki University Hospital Finland

9. Department of Pulmonary Medicine, Heart and Lung Center and Cancer Center Helsinki University Hospital Finland

10. iCAN Digital Precision Cancer Medicine Flagship Finland

11. Translational Cancer Medicine Research Program, Faculty of Medicine University of Helsinki and Helsinki University Hospital Finland

12. Biotech Research & Innovation Centre (BRIC) and Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) University of Copenhagen Denmark

Funder

Helsinki Institute of Life Science, Helsingin Yliopisto

Suomen Lääketieteen Säätiö

K. Albin Johanssons Stiftelse

Horizon 2020 Framework Programme

Novo Nordisk Fonden

Sigrid Juséliuksen Säätiö

Academy of Finland

Helsingin Yliopisto

Helsingin ja Uudenmaan Sairaanhoitopiiri

Biomedicum Helsinki-säätiö

Syöpäsäätiö

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.13342

Reference41 articles.

1. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

2. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

3. Targeting ALK: Precision Medicine Takes on Drug Resistance

4. Tyrosine kinase gene rearrangements in epithelial malignancies

5. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance;JTO Clinical and Research Reports;2024-09

2. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

3. Peristromal niches protect lung cancers from targeted therapies through a combined effect of multiple molecular mediators;2024-04-25

4. Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023);Expert Opinion on Therapeutic Patents;2024-03-03

5. Development of small-molecule inhibitors that target PI3Kβ;Drug Discovery Today;2024-01